Search

Displaying results 4971 - 4980 of 8698 in total
  1. Drug

    GC012F

    go.drugbank.com/drugs/DB22406
    Investigational

    GC012F is under investigation in clinical trial NCT06419166 (An Exploratory Clinical Study of GC012F Injection for Refractory gMG).

  2. Drug

    Prosetin

    go.drugbank.com/drugs/DB18649
    Investigational

    Prosetin is an orally administered blocker of MAP4K under investigation for the treatment of amyotrophic lateral sclerosis.[L48360]

  3. Drug

    Rovaleucel

    go.drugbank.com/drugs/DB18691
    Investigational

    Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.

  4. Drug

    Autologous DNP-conjugated tumour vaccine

    go.drugbank.com/drugs/DB17361
    Investigational

    Autologous DNP-conjugated tumour vaccine, or melanoma vaccine, is an investigational autologous cell vaccine technology for melanoma.[A254806]

  5. Drug

    OPC1

    go.drugbank.com/drugs/DB17944
    Experimental

    OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.[L47082]

  6. Drug

    HMR4011

    go.drugbank.com/drugs/DB06225
    Experimental

    IPL 576,092 has previously been investigated as a treatment for asthma.

  7. Drug

    GTS-21

    go.drugbank.com/drugs/DB05708
    Investigational

    GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  8. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  9. Target

    Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1

    go.drugbank.com/bio_entities/BE0004522
    TargetTransporterHumans

    Inositol 1,4,5-trisphosphate-gated calcium channel that, upon inositol 1,4,5-trisphosphate binding, mediates calcium release from the endoplasmic reticulum (ER) (PubMed:10620513, PubMed:27108797). Undergoes conformational changes upon li...

    Synonyms: IP3 receptor isoform 1, Type 1 InsP3 receptor
  10. Drug

    G17DT Immunogen

    go.drugbank.com/drugs/DB04914
    Investigational

    It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan … It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine.

    Synonyms: G17DT (AN ANTIGASTRIN IMMUNOGEN)